Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer.

BTX-9341 - BioTheryX

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Verzenio (abemaciclib) - Eli Lilly

fulvestrant - Generic mfg.

atirmociclib (PF-07220060) - Pfizer

https://sabcs.org/Portals/0/Documents/Formatted_Abstracts%2011-27%20Without%20Embargoed.pdf?ver=qjVzk5LPNjOteEIvNEYJFw%3d%3d

Hannah Majeski; Kirti Kandhwal Chahal; Angela Pasis; Casey Carlson; Qiao Liu; Arvind Shakya; Akinori Okano; Shenlin Huang; Aparajita Chourasia; Leah Fung

Nov 2, 2024